Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

HealthRX vs Bodi Envi

Two GLP-1 desks, one scoreboard. We put HealthRX and Bodi Envi head-to-head on the published Brief Score — the same six factors, scored the same way.

Higher Brief ScoreNo. 7 · Grade B

HealthRX

Visit HealthRX Full brief →
vs
No. 113 · Grade C

Bodi Envi

Visit Bodi Envi Full brief →

The verdict

HealthRX takes this head-to-head.

HealthRX scores 86 to 71 on our six-factor Brief Score — A LegitScript-certified, physician-supervised desk (healthrx.com) whose real hook is breadth: injectable and a rare oral GLP tablet, on both molecules, with transparent no-insurance monthly pricing.

That doesn't make Bodi Envi a bad call — it's best for readers who want transparent flat-price compounded semaglutide & tirzepatide with no membership fee. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
85
78
Supply Reliability
85
72
Transparency
83
72
Access Breadth
91
50
Clinical Oversight
89
83
Track Record
81
68
HealthRXBrief Score 86 · 71Bodi Envi

Price, coverage & the tracker

HealthRXBodi Envi
Brief Score86/100 (B)71/100 (C)
Semaglutide$189/mo$179/mo
Tirzepatide$349/mo$249/mo
CoverageNot publicly listedCoverage not published
Brand-name accessYesCompounded only
Oral / sublingualYesInjection only
On the trackerStableprice stableNewnew to the tracker, no prior reading

HealthRX: Company-stated tiers held flat this cycle; the LegitScript badge and a rare oral GLP tablet are the draw, but some tiers are self-reported rather than checkout-verified.

Bodi Envi: New to the tracker on 1 August 2026. The published line reads $179/mo at our first reading; there is no earlier reading of ours to compare it against yet.

Not sold on either?

CoreAge Rx tops the whole board at 94/100.

The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.